A Foundation of Clinical Experience.

Linnaeus is a Penn Center for Innovation UPstart company that was founded in 2016 and is based upon discoveries from the Ridky lab at the University of Pennsylvania. We are developing our initial therapies that are supported by a foundation of clinical experience. Being female and having a history of pregnancy are associated with decreased incidence and improved stage specific survival for many cancers, including melanoma, pancreatic ductal adenocarcinoma, non-small cell lung cancer, and colon carcinomas.

See our video here.

Our approach

Applied Knowledge

We believe that if you observe the clinical experience and listen to what it tells us, it will lead to the identification of new therapeutic targets for cancer.

Diverse Team

We have assembled a management and development team with complementary skill sets and differing areas of domain expertise that should allow us to get our drug-candidates into humans as safely and as quickly as possible.

Latest News

Company & industry updates from the Linnaeus team

Linnaeus Therapeutics Closes $4.4 Million Series A Financing

Linnaeus Therapeutics, Inc. (“Linnaeus”), a privately held biopharmaceutical company focused on the development and commercialization of novel, small molecule oncology therapeutics, today announced that it has closed a $4.4 million series A financing. Kairos Ventures, of Beverly Hills, California, led the financing with significant participation from the University of Pennsylvania, Linnaeus CEO, Patrick Mooney, and Linnaeus SVP, R&D, Tina Garyantes.

Read latest news

We Listen to the Clinical Experience

We allow it to inform the science that drives the development of new treatments to treat cancer.

Contact Us